SCLX | Complete Scilex Holding Co. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Scilex Holding Co 致力于收购、开发和商业化用于治疗急性和慢性疼痛的非阿片类疼痛治疗产品。公司的商业产品 ZTlido(利多卡因外用系统)是一种处方利多卡因外用产品,用于缓解带状疱疹后神经痛,是一种带状疱疹后神经痛引起的疼痛。该公司致力于将 Gloperba(秋水仙碱 USP)口服溶液商业化,这是一种预防性治疗成人痛...
Scilex Holding Co 致力于收购、开发和商业化用于治疗急性和慢性疼痛的非阿片类疼痛治疗产品。公司的商业产品 ZTlido(利多卡因外用系统)是一种处方利多卡因外用产品,用于缓解带状疱疹后神经痛,是一种带状疱疹后神经痛引起的疼痛。该公司致力于将 Gloperba(秋水仙碱 USP)口服溶液商业化,这是一种预防性治疗成人痛...
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated...
Scilex Holding Company, a subsidiary of Sorrento Therapeutics, Inc., announced that the Company’s 2023 Annual Meeting of Stockholders that was scheduled to be held at 9:00 a.m. on Thursday, April 6, 2023, has been postponed to April 17, 2023 at 9:00 a.m
risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other simi...
HC Wainwright & Co.:维持Scilex Holding(SCLX.US)评级,由买入调整至买入评级, 目标价由12.00美元调整至8.00美元。 Scilex Holding(SCLX.US)公司简介:Scilex Holding Co 从事非阿片类药物疼痛管理产品的开发和商业化发展。 该公司的主导产品 为ZTlido。
Scilex Holding Co(SCLX)公告一览 代码名称相关链接最新价涨跌额涨跌幅振幅成交量(股)成交额(美元)市盈率 SCLX Scilex Holding Co 行情 F10 股吧 - - - - - - -美股F10 核心必读 公司概况 财务分析 股本股东 分红派息 主营构成 高管研究 资产负债表 综合损益表 现金流量表 董事及股东权益 机构明细...
Scilex Holding Co 估值:7.00 10月21日Raghuram Selvaraju - HC Wainwright & Co. 对Scilex Holding Co(SCLX)给出Buy评级,并给出$7.00目标价格。 00 转发(0)评论(0)站内推送 Raghuram Selvaraju10/21 Scilex Holding Co 操作:买入 买入价:0.97
Market Cap $88M Current Price $0.45 ASX: MVP Medical Developments International Market Cap A$51M Current Price A$0.46 TSX: CWEB Charlotte's Web Market Cap CA$31M Current Price CA$0.20 Premium Investing Services Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, an...